SCHEMBL9944332

SCHEMBL9944332

Cc1cc(NC(=O)c2cc(Cl)c(Cl)c(OC(C)C)c2)ccc1C=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.45
KCNK3 O14649 1/20 0.41
KCNK9 Q9NPC2 1/20 0.41
PLAU P00749 1/20 0.41
MAPT P10636 5/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 1/20 0.40
FKBP5 Q13451 1/20 0.40
NPC1 O15118 7/20 0.40
RAB9A P51151 7/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
KCNQ3 O43525 1/20 0.40
KCNQ2 O43526 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
MEN1 O00255 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944353 0.88 TAS1R3 (0.50) RORCPLAUMAPTALDH1A1MAPK1
SCHEMBL9944283 0.87 PLAU (0.47) RORCPLAUMAPTFKBP5NPC1
SCHEMBL9944331 0.86 RAB9A (0.49) RORCPLAUMAPTALDH1A1MAPK1
SCHEMBL9944328 0.85 RAB9A (0.43) RORCKCNK3KCNK9PLAUMAPT
SCHEMBL9944245 0.84 RORC (0.50) RORCKCNK3KCNK9PLAUMAPT
SCHEMBL9944342 0.84 MAPT (0.49) MAPTALDH1A1MAPK1NPC1RAB9A
SCHEMBL9944304 0.83 MAPT (0.50) PLAUMAPTALDH1A1MAPK1NPC1
SCHEMBL1458469 0.83 NPC1 (0.47) RORCKCNK3KCNK9MAPTALDH1A1
SCHEMBL1457743 0.82 MAPT (0.47) RORCKCNK3KCNK9PLAUMAPT
SCHEMBL9944336 0.81 TP53 (0.51) PLAUMAPTALDH1A1MAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG RORC 10/4885KCNK3 4768/4885KCNK9 4365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.